Wednesday, July 8, 2026

pharma · Pyruvate Kinase Deficiency · Sickle Cell Disease · AGIO

Agios Netherlands

Agios Netherlands is a pharma organization headquartered in CAMBRIDGE, MA, NL. It trades on NYSE under ticker AGIO. Primary therapeutic focus areas include Pyruvate Kinase Deficiency, Sickle Cell Disease, Transfusion-dep

CAMBRIDGE, MA, NL HQ
1978 Founded
20 Employees
Public company Type
AGIO · NYSE Ticker
Company details
Status
Public
HQ
CAMBRIDGE, MA, NL
Founded
1978
Employees
20
Programs
45
Drugs
15
Patents
93
Clinical program

Mitapivat tablet

Phase 1 · small molecule · Healthy Volunteers

Mitapivat tablet for Healthy Volunteers is a Phase 1 program (small_molecule) at Agios Netherlands B.V. with 1 ClinicalTrials.gov record(s).

← All Agios Netherlands B.V. projects Phase 1 small molecule completed

Internal code AG348-C-021

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Agios Netherlands B.V.
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Volunteers
Status
completed
Trials
1